1	NOTCH1	fusions in	pediatric	T-cell ly	ymphob	lastic lyr	mphoma:	a high-risk
---	--------	------------	-----------	-----------	--------	------------	---------	-------------

2 subgroup with CCL17 (TARC) levels as diagnostic biomarker

- 3
- 4 Emma Kroeze¹, Michelle M Kleisman¹, Lennart A Kester¹, Marijn A Scheijde-Vermeulen¹,
- 5 Edwin Sonneveld¹, Jessica GC Buijs-Gladdines¹, Melanie M Hagleitner¹, Friederike AG Meyer-
- 6 Wentrup¹, Margreet A Veening¹, Auke Beishuizen¹, Jules PP Meijerink^{1,+}, Jan LC Loeffen^{1*},
- 7 Roland P Kuiper^{1,2}*
- 8
- 9 ¹Princess Máxima Center for pediatric oncology, Utrecht, the Netherlands
- ²Department of Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, the
- 11 Netherlands
- 12 ^{*T}Presently working at Acerta-Pharma (AstraZeneca), Oss, the Netherlands*</sup>
- 13 *JLCL and RPK are considered co-last authors
- 14
- Corresponding author: Prof. dr. Roland P Kuiper, Princess Maxima Center for Pediatric
 Oncology, Heidelberglaan 25, 3584 CS Utrecht, Netherlands,
 r.kuiper@prinsesmaximacentrum.nl
- 18
- 19
- 20 Abstract

Twenty percent of children with T-cell lymphoblastic lymphoma (T-LBL) will relapse and have an extremely poor outcome. Currently, we can identify a genetically low-risk subgroup in pediatric T-LBL, yet these high-risk patients who need intensified or alternative treatment options remain undetected. Therefore, there is an urgent need to recognize these high-risk T-LBL patients through identification of molecular characteristics and biomarkers. By using RNA sequencing which was performed in 29/49 T-LBL patients who were diagnosed in the

Princess Maxima Center for Pediatric Oncology between 2018-2023, we discovered a 27 previously unknown high-risk biological subgroup of children with T-LBL. This subgroup is 28 29 characterized by NOTCH1 gene fusions, found in 21% of our T-LBL cohort (6/29). All patients 30 presented with a large mediastinal mass, pleural/pericardial effusions, and absence of blasts in the bone marrow, blood, and central nervous system. Blood CCL17 (C-C Motif Chemokine 31 32 Ligand 17, TARC) levels were measured at diagnosis in 26/29 patients, and all six patients 33 with *NOTCH1* gene fusions patients exclusively expressed highly elevated blood CCL17 levels. defining a novel and previously not known clinically relevant biomarker for T-cell 34 35 lymphoblastic lymphoma. Four out of these six patients relapsed during therapy, a fifth 36 developed a therapy related acute myeloid leukemia during maintenance therapy. These 37 data indicate that T-LBL patients with a NOTCH1 fusion have a high risk of relapse which can 38 be easily identified using a blood CCL17 screening at diagnosis. Further molecular 39 characterization through *NOTCH1* gene fusion analysis offers these patients the opportunity for treatment intensification or new treatment strategies. 40

41

42 Introduction

T-cell lymphoblastic lymphoma (T-LBL) is a common pediatric malignancy accounting for
approximately 20% of the non-Hodgkin lymphomas during childhood¹. Survival rates of TLBL are ~80%, but outcome after relapse is dismal, with salvage rates reaching only ~15%^{2,3}.
Considering the extremely poor prognosis after relapse and absence of clinically relevant
high-risk genetics, there is an urgent need for the identification of molecular risk factors and
new prognostic biomarkers in T-LBL, as well as identification of new therapeutic strategies.

Pediatric T-LBL is typically characterized by infiltration of blasts in the mediastinum (thymus) 49 and lymph nodes. Approximately half of the cases present with pleural effusion at diagnosis 50 and, by definition, T-LBL patients have less than 25% blasts in the bone marrow $(BM)^{4.5}$. 51 Based on morphology and immunophenotype, T-LBL is indistinguishable from its leukemic 52 53 counterpart, T-cell acute lymphoblastic leukemia (T-ALL). T-ALL presents as leukemic disease 54 with \geq 25% blasts in the BM and presence of blasts in the peripheral blood (PB), but usually 55 with mild mediastinal enlargement. Even though the clinical presentation of T-LBL and T-ALL 56 largely differs, there has been no evidence so far that there are major differences in molecular genetics of T-LBL and T-ALL^{6,7}. Therefore, T-LBL and T-ALL are regarded as 57 different manifestations of the same disease⁸. Pediatric T-ALL has been extensively studied 58 59 and great advances in treatment protocols have been made, including minimal residual 60 disease (MRD) measurements as a useable stratification strategy. In contrast, molecular 61 genetics underlying T-LBL are still poorly understood and T-LBL patients are currently mainly 62 treated according to ALL-based protocols. Thus far, MRD assessment has not proven to be 63 usable in T-LBL and diagnostic biomarkers to identify high-risk patients are lacking.

Diagnostic biomarkers have been successfully introduced in other types of lymphomas. For 64 65 example, CCL17, also known as blood thymus and activation-regulated chemokine (TARC) has proven to be a useful diagnostic biomarker in children with classical Hodgkin 66 lymphoma^{9,10}. It has never been studied whether CCL17 can serve as a biomarker in non-67 Hodgkin lymphoma and T-LBL in particular. CCL17 is constitutively produced in the thymus, 68 69 acting as a powerful T-cell chemoattractant. In classical Hodgkin lymphoma patients, CCL17 production can be induced by NOTCH1 and CCL17 is highly expressed by the Reed-Sternberg 70 cells, thereby creating a specific supporting tumor microenvironment that recruits T-cells¹⁰. 71

72	Considering the importance of NOTCH1 and strong preference of malignant T-cells in T-LBL
73	for the thymus, we hypothesize that CCL17 is of importance in the pathophysiology of T-LBL
74	and creating a thymic microenvironment that favors the T-LBL cells.
75	Recent studies show that both T-LBL and T-ALL patients with NOTCH1 and/or FBXW7 DNA
76	mutations have a better outcome compared to <i>NOTCH1</i> and <i>FBXW7</i> wildtype patients 11,12 .
77	The pathogenic molecular mechanisms of T-LBL patients without NOTCH1 and/or FBXW7
78	mutations remain largely unknown, and this group probably contains both high-risk and low-
79	risk patients. Considering the extremely poor prognosis after relapse, it is essential to
80	identify these high-risk patients. Additionally, there is an urgent need for the identification
81	of new prognostic biomarkers in T-LBL. In this study we present a novel entity of pediatric T-
82	LBL patients characterized by previously unknown NOTCH1 gene fusions, high risk of relapse,
83	and highly elevated blood CCL17 (TARC) levels

84

85

86 Methods

87 Patients

We included a complete cohort of all pediatric T-LBL patients (n=49) that were diagnosed in the Princess Máxima Center for Pediatric Oncology between 2018-2024. RNA sequencing data at diagnosis were available for 29/49 patients and at relapse for two additional patients. Clinical information and hematological values at diagnosis were retrieved from patient files. All patients were treated according to the EURO-LB02 protocol³ or its successor, the LBL2018 protocol (NCT04043494). *NOTCH1/FBXW7* mutational status was determined

for most patients and retrieved from patient files. Pediatric T-ALL patients (n=39) diagnosed between 2019-2022 at the Princess Máxima Center for Pediatric Oncology were included as reference cohort. All sample IDs are completely anonymized. Written informed consent was obtained from all patients and/or their legal guardians included in this study. The study was performed in accordance with the Declaration of Helsinki. The Medical Research Ethical Committee Utrecht declared that the Medical Research Involving Human Subjects Act (WMO) does not apply, and has approved the study (19-140/C).

101

102 **RNA sequencing analysis**

103 RNA sequencing data was obtained from the in-house diagnostics department in the 104 Princess Máxima Center. The source of biological material is given in **Supplementary Table 1**. 105 Pre-processing of the data was done with standardized and in-house pipelines and guidelines¹³. Fusion detection was performed using STAR fusion¹⁴. In addition, we analyzed 106 107 the entire T-LBL and T-ALL cohort for exon-specific NOTCH1 coverage as an indication for 108 fusions, by using DepthOfCoverage of GATK v3.8.0. Whole genome sequencing data (WGS) were also obtained from the in-house diagnostics department and used for validation of 109 110 genomic breakpoints.

111

112 Gene expression analyses

For expression analyses, samples with less than 30 million unique reads were excluded due to lower quality (TLBL042, TLBL046 and TLBL058). For TLBL042, expression data from the relapse were used (TLBL042 R). Gene expression alterations were assessed with log2

transformed gene length normalized read counts (transcript per million mapped reads, TPM)
using R v4.4.0. Gene expression variance was determined by calculating standard deviations
and the 200 most variable genes were taken in unsupervised clustering using Euclidean
distance as a measure of similarity. The R package pheatmap v1.0.12 was implemented for
visualizations.

121

Differential expression analyses were performed with DESeg2 v1.36.0¹⁵ between NOTCH1-122 123 rearranged- and WT cases and between NOTCH1-mutated- and WT cases. Differentially 124 expressed genes were identified after adjustment for false discovery rate (FDR-adjusted p-125 value \leq 0.05). Visualisations were generated using R packages EnhancedVolcano v1.12.0 and 126 pheatmap v1.0.12. Subsequently, gene set enrichment analysis (GSEA) was conducted for biological interpretations with cluster Profiler v4.12.0 16,17 . Genes were ranked according to 127 direction-signed log10-transformed p-values, as determined by DESeq2 v1.36.0, and 128 129 annotations were provided by implementing the R package AnnotationHub v3.2.2. The 130 ranked gene list was used for Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway 131 enrichment analysis. Additionally, z-scores of log2-transformed TPM values were calculated 132 within the complete T-LBL cohort for genes associated with the NOTCH signaling pathway. 133 ClusterProfiler v4.12.0 and ComplexHeatmap v2.10.0 were implemented for GSEA-result 134 visualizations.

135

136 CCL17 (TARC) measurements and immunohistochemistry

137 CCL17 measurements at diagnosis were performed in serum or plasma of 26 out of the 29 patients for whom RNAseq was available. Measurements were performed in triplo by 138 139 standard enzyme-linked immunosorbent assay (ELISA) using the DuoSet ELISA kit (cat. no. 140 DY364; R&D Systems, Inc.). Immunohistochemistry staining for CCL17 was performed on the 141 BOND-III fully automated staining system (Leica, IL, USA) using CCL17 rabbit polyclonal 142 antibody (ProteinTech group, Chicago IL, USA). Significance of CCL17 expression between 143 NOTCH1-rearranged samples and the rest of the T-LBL RNAseq cohort was determined using 144 DESeq2 v1.36.0.

145

146 Results

147 *Patient characteristics*

148 The pediatric T-LBL patients included in this study (n=49) represented an unselected 149 complete cohort diagnosed in the Princess Máxima Center for Pediatric Oncology between 2018-2023. T-LBL diagnoses were based on histopathological classification according to the 150 151 revised world health organization for hematological malignancies and/or flow cytometry according to the criteria of the European Group for Immunophenotyping of Leukemias^{8,18}. 152 153 Six out of 49 patients (12%) had a relapse. Informed consent was obtained for 45/49 T-LBL 154 patients and these were therefore used for further analysis. The median age at diagnosis for these 45 patients was ten years, and our cohort contained more males than females (59%), 155 in line with previously described large T-LBL cohorts³. Eighty-eight percent of the patients 156 157 presented with a large mediastinal mass, which was in 56% of these cases accompanied by 158 pleural effusion. RNAseg was performed for 29/43 patients and their clinical characteristics 159 are described in Supplementary Table 1.

160

161 **Detection of NOTCH1 rearrangements**

162 Transcriptome sequencing was performed at diagnosis from 2019 onwards for all samples 163 with sufficient good quality material available (n=29). This technique allows for the 164 identification and quantification of fusion transcripts and gene expression levels. We 165 identified 12 fusions transcripts in total (12/29, 41%), of which six were NOTCH1 gene fusions. Fusion partner of NOTCH1 werethe microRNA gene miR142HG on chromosome 166 17g22 (TLBL042 and TLBL058), IKZF2 on chromosome 2g34 (TLBL050) and TRBJ on 167 chromosome 7q34 (TLBL033, TLBL049, TLBL050) (Supplementary Table 2). The 168 169 TRBJ::NOTCH1 fusions were missed by fusion detection algorithms, but were detected 170 because of pronounced expression differences between exons in the 5' and 3' part of the 171 gene (see Methods). The fusion transcripts with miR142HG and IKZF2 demonstrated correct splicing to exon 27 or 28 of NOTCH1 and genomic breakpoints were identified using available 172 whole genome sequencing (WGS) data (Supplementary Table 2). TRBJ::NOTCH1 fusion 173 genes were previously shown to express a truncated, membrane-bound form of NOTCH1¹⁹ 174 175 (Figure 1A). None of the six samples with a NOTCH1 gene fusion exhibited mutations in 176 NOTCH1/FBXW7, demonstrating the mutual exclusivity of NOTCH1 mutations and NOTCH1-177 rearrangements. Furthermore, apart from homozygous loss of the CDKN2A/2B locus in two cases (TLBL042 and TLBL050), no other driver events were found in these NOTCH1-178 179 rearranged T-LBLs. NOTCH1 gene fusions are almost never found in T-ALL, but considering 180 the difficulties in detecting TR-rearranged fusions with conventional pipelines, we also reanalyzed exon-specific NOTCH1 expression in 39 T-ALL samples that were diagnosed in the 181 Princess Máxima Center for Pediatric Oncology. In line with previous studies^{20,21}, none of the 182

T-ALL samples carried gene fusions involving *NOTCH1*, thus suggesting that the frequent
occurrence of these fusions represents an important molecular genetic discriminator
between T-LBL and T-ALL.

186

187

All NOTCH1 gene fusions result in expression of intracellular NOTCH1

NOTCH1 is a transmembrane protein that is activated through ligand-receptor interaction, which induces a conformational change that results in dissociation of the heterodimerization (HD) subunits. This is followed by exposure of a cleavage site in the C-terminal part of the HD domain, resulting in the release of the intracellular domain of NOTCH1 (NICD). NICD subsequently translocates to the nucleus where it acts as a transcriptional regulator²².

193 To determine whether a truncated C-terminal version of NOTCH1 was indeed expressed in 194 the T-LBL samples with a NOTCH1-rearrangement, we performed Western blotting using 195 protein lysates of four NOTCH1-rearranged cases and two NOTCH1 wildtype (NOTCH1-WT) cases. All NOTCH1-rearrangements lead to expression of NICD. The IKZF2::NOTCH1-positive 196 197 T-LBL (TLBL050) showed expression of an NICD protein co-migrating with the ~130-kDa 198 wildtype NICD, suggesting cleavage of the chimeric protein at the 2-secretase cleavage side 199 (Val1744). In contrast, the TRBJ::NOTCH1-positive (TLBL033 and TLBL052) and *miR142HG::NOTCH1*-positive (TLBL042) cases expressed a slightly larger NICD protein, which 200 201 is in line with translation initiation at methionine residue 1727 (Met1727) encoded in exon 28 of *NOTCH1*, as previously reported^{19,23}, and lack of ^[2]-secretase cleavage (**Figure 1B**). 202

To explore the downstream consequences of T-LBL cases with a *NOTCH1* fusion in our T-LBL cohort, we performed unsupervised clustering analysis with the 200 most variable genes in

205 the dataset (Supplementary Table 3), which showed that NOTCH1-rearranged samples 206 mostly clustered together (Supplementary Figure 1). These data indicate that NOTCH1-207 rearranged samples display similar expression profiles among each other. Next, we 208 performed differential expression analysis between NOTCH1-rearranged and NOTCH1-WT T-209 LBLs, to determine expression differences. A total of 1,288 genes were found to be 210 significantly differentially expressed, compared to only 101 genes in a comparison between 211 NOTCH1-mutated and NOTCH1-WT T-LBLs (Figure 2A,B and Supplementary Tables 4 and 5). 212 These data indicate that NOTCH1-mutated and NOTCH1-WT cases exhibit comparable 213 expression profiles, whereas NOTCH1-rearranged cases differ substantially from the rest of 214 the cohort. Subsequently, we selected the 200 most significantly differentially expressed 215 genes between NOTCH1-rearranged and NOTCH1-WT T-LBLs for supervised clustering. This 216 analysis revealed that NOTCH1-rearranged samples formed a separate cluster, whereas the 217 NOTCH1 mutated and NOTCH1-WT cases are mixed in a second cluster (Figure 2C), confirming the unique characteristics of the NOTCH1 fusion samples. 218

219 To explore downstream characteristics of NOTCH1-rearranged cases, we performed GSEA, to 220 determine enriched KEGG pathways (Supplementary Figure 2A). Among others, the NOTCH 221 signaling pathway was significantly activated in NOTCH1-rearranged samples compared to 222 NOTCH1-WT samples, with an enrichment score of 0.695 (adj. p-value=0.0003 (Figure 3A,B). 223 Enrichment of KEGG pathways was to a lesser extent observed in NOTCH1-mutated cases 224 compared to NOTCH1-WT samples, including no significant enrichment of the NOTCH 225 signaling pathway (Supplementary Figure 2B). These findings suggest that the downstream characteristics and mechanisms of action of the NOTCH1-rearranged samples are different 226 227 from both wildtype and mutant T-LBL samples.

228

229 Clinical presentation of patients with NOTCH1 gene fusions

All six patients with NOTCH1 gene fusions presented with a massively enlarged 230 231 mediastinum, combined with pleural/pericardial effusion. Moreover, all NOTCH1 gene 232 fusion-positive patients were bone marrow negative, peripheral blood negative and cerebral 233 spinal fluid negative. These patients therefore had a uniform clinical presentation of disease, 234 although not differentiating between this group and the rest of the T-LBL cohort. 235 Flowcytometry performed at diagnosis revealed positivity for cytoplasmatic CD3 (cyCD3) in 236 all cases, as well as positivity for other T-cell markers. Precursor-marker Terminal Deoxynucleotidyl Transferase (TdT) was expressed in 50% of the NOTCH1-rearranged cases, 237 which was lower than expected (~90%)²⁴ (**Supplementary Table 6**). Next, we analyzed blood 238 239 CCL17 levels, which were highly elevated in all patients with a NOTCH1 gene fusion (range 240 from 2345 to >10000 pg/ml), compared to 31-638 pg/ml in 16 patients who did not have a NOTCH1 gene fusion (p<0.0001, t-test) (Figure 4A). Follow-up CCL17 levels during first 241 242 remission were available for 3/6 patients and revealed normalized values (range 57-152 243 pg/ml) (Figure 4B). Three of the patients with a clinical relapse (TLBL042, TLBL050 and 244 TLBL058) also showed substantially elevated CCL17 levels at relapse (TLBL042:4613 pg/ml, 245 TLBL050:8654 pg/ml, TLBL058:1662 pg/ml), which could be an indication that CCL17 levels 246 in blood might also increase upon progression of relapse. One patient, whose relapse was 247 discovered with routine imaging, presented with relatively little tumor load and low LDH 248 levels, and did not have increased CCL17 levels (TLBL033) at time of establishing the relapse. CCL17 levels decreased again in second remission (range 69-1331 pg/ml) (Figure 4C). 249 250 Although immunohistochemistry did not reveal positivity of the T-LBL cells for CCL17 (Figure

4D), based on gene expression, *CCL17* was significantly upregulated in the *NOTCH1*rearranged cases compared to the rest of the T-LBL cohort (FDR-adjusted p-value=0.019). Together, our data strongly indicate that CCL17 can serve as a high-risk biomarker at diagnosis.

255

256 NOTCH1 gene fusions as poor prognostic marker in T-LBL

257 Finally, we aimed to determine the prognostic relevance of NOTCH1 gene fusions in T-LBL. 258 We found that five out of six NOTCH1 fusion-positive patients had an event. Four patients 259 had a relapse during therapy (TLBL033, TLBL042, TLBL050, TLBL058), one of them is still 260 under treatment, the other three could not be rescued. Additionally, one patient had a 261 therapy-related acute myeloid leukemia (t-AML) during maintenance therapy of T-LBL 262 (TLBL049), leaving just one NOTCH1-fusion positive patient without an event. The t-AML carried the typical KMT2A::MLLT3 fusion. This patient was rescued with AML induction 263 264 chemotherapy followed by allogeneic stem cell transplantation. The sixth NOTCH1-fusion 265 positive patient did not have an event, yet this patient is still under maintenance treatment. 266 In the rest of the cohort, one event occurred, which was death due to pancreatitis 267 complicated by a septic shock (Figure 5). Our data therefore shows a significant difference in 268 cumulative incidence of events between the NOTCH1-fusion group and the rest of the 269 cohort (p<0.001)

The unselected 5-year T-LBL cohort (n=49) contained six patients who relapsed, of whom four had a *NOTCH1* gene fusion. For the other two patients, only RNAseq data at relapse was available, revealing a *DDX3X*::*MLLT10* fusion and a *JAKMIP2*::*PDGFRB* fusion at relapse, respectively, established high-risk ALL aberrations^{20,25}. Thus, *NOTCH1*-rearranged T-LBL

caused the majority of relapses in our cohort, suggesting that they cause an aggressive T-LBL
phenotype, with a significantly higher cumulative incidence of relapse (p<0.001, Gray's test)
compared to the *NOTCH1*-fusion negative patients.

277

278 Discussion

To date, mainly clinically applicable low-risk genetics have been described for T-LBL. This implicates that molecular genetic high-risk patients who need intensified or alternative treatment strategies are undetected. Moreover, patients with unknown low-risk molecular genetic profiles could also be overtreated with current treatment strategies.

283 We discovered a biological high-risk subgroup of T-LBL, characterized by NOTCH1 gene 284 fusions. This subgroup represents 21% (6/29 patients) of our T-LBL cohort. All patients had a 285 similar although not unique presentation of disease predominantly consisting of a large 286 mediastinal mass, pleural/pericardial effusion and highly elevated CCL17 (TARC) levels in blood. Moreover, four out of six patients with a NOTCH1 gene fusion had a relapse and did 287 288 not survive, indicating that *NOTCH1* fusions lead to an aggressive T-LBL phenotype. Fifty 289 percent of the NOTCH1-rearranged cases exhibited expression of TdT, which is lower than 290 the expected 90%. It has been described before that the TdT-negative subset often 291 represent diagnostically challenging cases with phenotypic features that are consistent with a late cortical subtype, coinciding with what we found in our cohort²⁴. 292

The presence and frequency of *NOTCH1* gene fusions can currently be regarded as a major molecular genetic difference between T-LBL and T-ALL, since fusions involving *NOTCH1* are only extremely rarely described in T-ALL (<0.1%)^{21,26-31}. The uniform absence of BM and PB

involvement in T-LBL patients with a *NOTCH1* gene fusion coincides with the fact that these
rearrangements have almost never been detected in T-ALL. *NOTCH1* gene fusions have been
described in T-LBL before²⁸, but given the small number of samples in these studies, as well
as difficulties in detecting TR-rearranged fusions with conventional pipelines, these fusions
might have been missed explaining the lower contribution of *NOTCH1* gene fusions in these
studies.

302 NOTCH1 gene fusions appear to have more impact on T-LBL cells compared to NOTCH1 303 mutations, with more and larger changes in the downstream gene expression and NOTCH1 activity, independent of the type of NOTCH1-fusion. Furthermore, whereas patients with 304 305 NOTCH1 and/or FBXW7 mutations are considered low risk and have a better outcome compared to NOTCH1 and/or FBXW7 WT patients^{11,12}, we demonstrate that the outcome of 306 307 these recurrent NOTCH1-rearranged T-LBLs is poor. It has recently been described that 308 NOTCH1 intronic single nucleotide variants (SNVs) and NOTCH1 intragenic losses were also associated with an inferior event-free and overall survival³¹, further substantiating that 309 distinct genetic aberrations in NOTCH1 have a different impact on outcome. The T-LBL 310 311 patients with high-risk NOTCH1 aberrations will probably need intensified or alternative 312 treatment strategies. A second consequence of our findings may be that when NOTCH1 gene 313 fusions are recognized as a separate high-risk group, the survival characteristics of the 314 remaining group of T-LBL patients with unknown molecular genetics improves and may 315 benefit from less intensified treatment.

The highly elevated blood CCL17 levels were exclusively observed in all T-LBL patients with a *NOTCH1*-rearrangement, even though almost all T-LBL patients had an enlarged mediastinum. Elevated CCL17 levels may therefore serve as an important biomarker to

319 assist in the diagnosis of this high-risk group at diagnosis. Moreover, there might be a 320 possibility that CCL17 levels could be used during follow-up as well, but these findings need 321 to be validated in larger cohorts. In classical Hodgkin lymphoma, It has been suggested that 322 inhibiting CCL17, produced by the Reed-Sternberg cells, may have therapeutic consequences 323 in classical Hodgkin lymphoma as inhibiting CCL17 can decrease the recruitment of T-cells, thereby affecting the supporting microenvironment³². Our data suggest that CCL17 protein 324 325 levels in the tumor cells of NOTCH1-rearranged tumor cells is only slightly increased and 326 rapidly secreted based on immunohistochemistry, while CLL17 gene expression and blood 327 levels are highly increased. This likely points towards active crosstalk between the tumor cells and the microenvironment³³. It is therefore intriguing to further explore whether 328 329 NOTCH1-rearranged T-LBLs are dependent on CCL17 expression and whether this would 330 provide opportunities for targeted treatment in a potentially high-risk subgroup of T-LBL. 331 Measuring blood CCL17 levels could also serve as an easily applicable technique to identify high-risk T-LBL patients in low- and middle-income countries with restricted access to next 332 333 generation sequencing techniques.

In conclusion, we discovered that, in contrast to T-ALL, *NOTCH1* gene fusions are common in T-LBL and represent a high-risk subtype with an easily applicable biomarker. The discovery of this clinically relevant high-risk T-LBL subgroup offers opportunities to develop intensified and targeted treatment strategies for this subgroup and decrease overtreatment in the remaining group of T-LBL patients.

339

340 Data sharing agreement

- 341 Exome and transcriptome data will be submitted to the European Genome-Phenome
- 342 Archive (EGA) for controlled-access data sharing (EGAS00001007703).

343

344 Author contributions

- 345 RK, JLCL, AB designed the study. EK wrote the manuscript and analyzed the data. MMK and
- 346 LAK performed the bioinformatic analyses. JGCB performed the wet lab analyses. ES
- 347 provided laboratory supervision. MSV performed the histological analyses. MMH, FAGM,
- 348 MAV were involved in data curation. JPPM acquired the funding.

349

350 Declaration of interests

351 None of the authors declare a conflict of interest.

352

353 References

1. Minard-Colin V, Brugieres L, Reiter A, et al. Non-Hodgkin Lymphoma in Children and

355 Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges

356 Ahead. J Clin Oncol 2015;33(27):2963-74. DOI: 10.1200/JCO.2014.59.5827.

- 357 2. Burkhardt B, Reiter A, Landmann E, et al. Poor outcome for children and adolescents with
- 358 progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-
- 359 frankfurt-muenster group. J Clin Oncol 2009;27(20):3363-9. DOI: 10.1200/JCO.2008.19.3367.
- 360 3. Landmann E, Burkhardt B, Zimmermann M, et al. Results and conclusions of the European
- 361 Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma.
- 362 Haematologica 2017;102(12):2086-2096. DOI: 10.3324/haematol.2015.139162.

- 363 4. Swerdlow SH, Campo E, Lee Harris N, et al. WHO Classification of Tumours of Haematopoietic
- and Lymphoid Tissues (Revised 4th edition). World Health Organization Classification of
- 365 Tumours. Lyon, France: International Agency for Research on Cancer (IARC); 2017.
- 366 5. Rosolen A, Perkins SL, Pinkerton CR, et al. Revised International Pediatric Non-Hodgkin
- 367 Lymphoma Staging System. J Clin Oncol 2015;33(18):2112-8. DOI:
- 368 10.1200/JCO.2014.59.7203.
- 369 6. Khanam T, Sandmann S, Seggewiss J, et al. Integrative genomic analysis of pediatric T- cell
- 370 lymphoblastic lymphoma reveals candidates of clinical significance. Blood 2020. DOI:
- 371 10.1182/blood.2020005381.
- 372 7. Bontoux C, Simonin M, Garnier N, et al. Oncogenetic landscape of T-cell lymphoblastic
- 373 lymphomas compared to T-cell acute lymphoblastic leukemia. Mod Pathol 2022;35(9):1227-
- 374 1235. DOI: 10.1038/s41379-022-01085-9.
- 375 8. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health
- 376 Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia

377 2022;36(7):1720-1748. DOI: 10.1038/s41375-022-01620-2.

- 378 9. Zijtregtop EAM, Diez C, Zwaan CM, Veening MA, Beishuizen A, Meyer-Wentrup FAG. Thymus
- 379 and activation-regulated chemokine (TARC) as treatment response marker for paediatric
- 380 Hodgkin lymphoma: A pilot study. Br J Haematol 2023;200(1):70-78. DOI:
- 381 10.1111/bjh.18473.
- 382 10. Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notch1
- 383 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell
 384 lymphoma. Blood 2002;99(9):3398-403. DOI: 10.1182/blood.v99.9.3398.
- 385 11. Bonn BR, Rohde M, Zimmermann M, et al. Incidence and prognostic relevance of genetic
- 386 variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood
- 387 2013;121(16):3153-60. DOI: 10.1182/blood-2012-12-474148.

- 388 12. Callens C, Baleydier F, Lengline E, et al. Clinical impact of NOTCH1 and/or FBXW7 mutations,
- 389 FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol
- 390 2012;30(16):1966-73. DOI: 10.1200/JCO.2011.39.7661.
- 391 13. Hehir-Kwa JY, Koudijs MJ, Verwiel ETP, et al. Improved Gene Fusion Detection in Childhood
- 392 Cancer Diagnostics Using RNA Sequencing. JCO Precis Oncol 2022;6:e2000504. DOI:
- 393 10.1200/PO.20.00504.
- Haas BJ, Dobin A, Stransky N, et al. STAR-Fusion: Fast and Accurate Fusion Transcript
 Detection from RNA-Seq. BioRxiv 2017.
- 396 15. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-
- 397 seq data with DESeq2. Genome Biol 2014;15(12):550. DOI: 10.1186/s13059-014-0550-8.
- Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes
 among gene clusters. OMICS 2012;16(5):284-7. DOI: 10.1089/omi.2011.0118.
- 400 17. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-
- 401 based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A

402 2005;102(43):15545-50. DOI: 10.1073/pnas.0506580102.

- 403 18. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute
- 404 leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).
- 405 Leukemia 1995;9(10):1783-6. (<u>https://www.ncbi.nlm.nih.gov/pubmed/7564526</u>).
- 406 19. Palomero T, Barnes KC, Real PJ, et al. CUTLL1, a novel human T-cell lymphoma cell line with
- 407 t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase

408 inhibitors. Leukemia 2006;20(7):1279-87. DOI: 10.1038/sj.leu.2404258.

- 409 20. Steimle T, Dourthe ME, Alcantara M, et al. Clinico-biological features of T-cell acute
- 410 lymphoblastic leukemia with fusion proteins. Blood Cancer J 2022;12(1):14. DOI:
- 411 10.1038/s41408-022-00613-9.
- 412 21. Brady SW, Roberts KG, Gu Z, et al. The genomic landscape of pediatric acute lymphoblastic
 413 leukemia. Nat Genet 2022;54(9):1376-1389. DOI: 10.1038/s41588-022-01159-z.

- 414 22. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation
- 415 mechanism. Cell 2009;137(2):216-33. DOI: 10.1016/j.cell.2009.03.045.
- 416 23. Ashworth TD, Pear WS, Chiang MY, et al. Deletion-based mechanisms of Notch1 activation in
- 417 T-ALL: key roles for RAG recombinase and a conserved internal translational start site in
- 418 Notch1. Blood 2010;116(25):5455-64. DOI: 10.1182/blood-2010-05-286328.
- 419 24. Patel JL, Smith LM, Anderson J, et al. The immunophenotype of T-lymphoblastic lymphoma
- 420 in children and adolescents: a Children's Oncology Group report. Br J Haematol
- 421 2012;159(4):454-61. DOI: 10.1111/bjh.12042.
- 422 25. Tasian SK, Loh ML, Hunger SP. Philadelphia chromosome-like acute lymphoblastic leukemia.

423 Blood 2017;130(19):2064-2072. DOI: 10.1182/blood-2017-06-743252.

- 424 26. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is
- 425 broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991;66(4):649-
- 426 61. DOI: 10.1016/0092-8674(91)90111-b.
- 427 27. Speleman F, Cauwelier B, Dastugue N, et al. A new recurrent inversion, inv(7)(p15q34), leads
- 428 to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic
 429 leukemias. Leukemia 2005;19(3):358-66. DOI: 10.1038/sj.leu.2403657.
- 430 28. Salmeron-Villalobos J, Ramis-Zaldivar JE, Balague O, et al. Diverse mutations and structural
- 431 variations contribute to Notch signaling deregulation in paediatric T-cell lymphoblastic

432 lymphoma. Pediatr Blood Cancer 2022;69(11):e29926. DOI: 10.1002/pbc.29926.

433 29. Yamamoto K, Nakamachi Y, Yakushijin K, et al. A novel TRB@/NOTCH1 fusion gene in T-cell

- 434 lymphoblastic lymphoma with t(7;9)(q34;q34). Eur J Haematol 2013;90(1):68-75. DOI:
- 435 10.1111/ejh.12019.
- 436 30. Liu Y, Easton J, Shao Y, et al. The genomic landscape of pediatric and young adult T-lineage
 437 acute lymphoblastic leukemia. Nat Genet 2017;49(8):1211-1218. DOI: 10.1038/ng.3909.
- 438 31. Mullighan C, Pölönen P, Giacomo DD, et al. [preprint] The genomic basis of childhood T439 lineage acute lymphoblastic leukemia. Research Square.

440 32. Zijtregtop EAM, van der Strate I, Beishuizen A, et al. Biology and Clinical Applicability of

- 441 Plasma Thymus and Activation-Regulated Chemokine (TARC) in Classical Hodgkin Lymphoma.
- 442 Cancers (Basel) 2021;13(4). DOI: 10.3390/cancers13040884.

443 33. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood

444 2002;99(12):4283-97. DOI: 10.1182/blood-2002-01-0099.

445

446 Figure legends

447 Figure 1: NOTCH1-rearrangements in T-LBL. A) Schematic representation of three different 448 NOTCH1 fusions with different fusion partners. The in-frame IKZF2::NOTCH1 fusion 449 generates a chimeric protein in which the N-terminal DNA binding domain of IKZF2 is fused 450 to the C-terminal intracellular domains of NOTCH1. Fusions transcripts with *miR142HG* and 451 TRBJ use an alternative translation start site in exon 28 (Met1727). B) Western blot analysis 452 using Val1744 antibody (Cell Signaling Inc.) shows that *miR142HG::NOTCH1* and the 453 TRBJ::NOTCH1 fusions lead to a larger NICD protein, likely representing uncleaved NICD with 454 translation initiation at Met1727. Simultaneous Beta-actin staining was performed for 455 loading comparisons.

456

457 Figure 2: Gene expression differences in NOTCH1-rearranged, mutated and wildtype T-LBL.

A+B) Volcano plots showing differentially expressed genes between *NOTCH1*-rearranged and *NOTCH1*-WT samples (n=1,288; panel A) and between *NOTCH1*-mutated and *NOTCH1* WT samples (n=101; panel B) C) Expression analysis of the 200 most significantly up- and downregulated genes (from a total of 1,288 genes) in *NOTCH1*-rearranged compared to *NOTCH1*-WT samples, revealed that *NOTCH1*-rearranged samples cluster separately from

463	NOTCH1 WT and NOTCH1-mutated samples using Euclidean distance as a measure of
464	similarity. The relapse sample of TLBL042 was used because of better quality. Range of 0-10
465	showing the log2-transformed TPM values. Significance was determined using false
466	discovery rate (FDR)-adjusted p-values.

467

468 Figure 3: GSEA results of the NOTCH signaling pathway. A) Enrichment plot for the NOTCH 469 signaling pathway in the NOTCH1-rearranged versus WT samples, showing the profile of the running enrichment score and positions of genes associated with this pathway on the rank-470 ordered gene list. B) Z-scores of log2-transformed TPM values of genes associated with the 471 472 NOTCH signaling pathway within the complete T-LBL cohort. Mean z-scores are depicted for 473 NOTCH1-rearranged, NOTCH1-mutated and WT samples. Genes are ranked based on their 474 position in the rank-ordered gene list used for GSEA between NOTCH1-rearranged and WT 475 samples.

476

477 Figure 4: CCL17 (TARC) in NOTCH1-rearranged patients. A) CCL17 levels in pg/ml per patient, showing highly elevated CCL17 in blood of NOTCH1-rearranged T-LBL patients but 478 479 none of the other patients. 10000 pg/ml is the maximum measurable CCL17 level with used 480 assay. Orange line in figure A, B and C represents maximum normal CCL17 level (1300 pg/ml) based on what has been described in Hodgkin lymphoma⁹. Patients that had a relapse are 481 482 indicated with an asterisk. Patient TLBL049 developed a therapy-related AML (double 483 asterisk). B) For three NOTCH1-rearranged patients, blood CCL17 levels could be determined for a time point of remission after diagnosis, revealing normalized CCL17 levels in all three 484 485 cases. C) For four NOTCH1-rearranged patients blood CCL17 levels were determined at time

486	point of relapse and remission after relapse (second remission), revealing increased levels in
487	three relapses that again normalized in second remission. D) Staining for TARC using anti-
488	CCL17 antibody for four NOTCH1-rearranged patients showing that T-LBL cells do not
489	express high levels of CCL17 based on immunohistochemistry.

490

491 Figure 5: Cumulative incidence plot of events reveals a significant higher cumulative

492 incidence of relapse in *NOTCH1*-rearranged cases compared to the rest of the T-LBL cohort

- 493 (3 years) (p<0.001). The p-value is estimated using Gray's test. Four relapses occurred in the
- 494 NOTCH1-rearranged cohort. No relapses occurred in the cohort. In both cohorts, one other
- 495 event occurred, which was a therapy related-AML in the *NOTCH1*-rearranged cohort and
- 496 death due to pancreatitis complicated by a septic shock in the other cohort.







-Log₁₀ P





В











